Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2018 · second_quarter · Q2
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Source: Senate LDA
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Abuse Deterrent Access Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Substance Abuse Prevention Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Substance Abuse Prevention Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Curb Opioid Misuse By Advancing Technology Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Curb Opioid Misuse By Advancing Technology Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Abuse-deterrent opioid exclusivity policy issues H.R. 2025, provisions related to abuse-deterrent opioid exclusivity
FDA Reauthorization Act of 2017
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Opioid Addiction Risk Transparency Act
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Opioid Addiction Risk Transparency Act
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids Provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Curb Opioid Misuse By Advancing Technology Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids Provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues
Curb Opioid Misuse By Advancing Technology Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2018 · first_quarter · Q1
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2017 · fourth_quarter · Q4
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2017 · third_quarter · Q3
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2017 · second_quarter · Q2
Abuse-deterrent opioid exclusivity policy issues H.R. 2025, provisions related to abuse-deterrent opioid exclusivity
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2017 · first_quarter · Q1
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids Provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2017 · first_quarter · RR
Abuse Deterrent Formulation(ADF)Legistlation
Abuse Deterrent Formulation(ADF)Legistlation
Abuse Deterrent Formulation(ADF)Legistlation
Provisions related to abuse-deterrent opioid exclusivity
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: HOUSE OF REPRESENTATIVES, SENATE